截至2月13日,Enveric Biosciences的空头股价下跌了20%,至62,034股,其中4.5%的股票被卖空. Short interest in Enveric Biosciences dropped 20% to 62,034 shares by Feb. 13, with 4.5% of shares sold short.

截至2月13日,Enveric Biosciences的空头股权下跌了20%,至62,034股,其中4.5%的股票被卖空,且1.3天的保证率. Short interest in Enveric Biosciences fell 20% to 62,034 shares by February 13, with 4.5% of shares sold short and a 1.3-day cover ratio. 按低于平均数量计算,库存以2.13美元关闭,减少0.12美元。 The stock closed at $2.13, down $0.12, on below-average volume. 该公司是一家临床阶段生物制药公司,开发基于精神错乱的心理治疗,市场上限为296万美元,P/E比率为负值。 The company, a clinical-stage biopharma firm developing psychedelic-based treatments for mental health disorders, has a market cap of $2.96 million and a negative P/E ratio. 分析师有好坏参半的评分,平均为120美元目标的“待发”评分。 Analysts have mixed ratings, averaging a "Hold" with a $120 target. 机构投资者拥有公司的13.82%。 Institutional investors own 13.82% of the company.